Heart failure & cardiomyopathies
Real-World Effectiveness of Targeted Therapies in ATTR Cardiomyopathy: A Meta-Analysis Integrating Population-Based Data
Authors' conclusion
Targeted treatments for ATTR-CM significantly reduce mortality and cardiovascular hospitalizations.
Study context
- Population
- Patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
- Participants
- 5,203 patients10 studies
- Comparison
- ATTR-targeted treatments vs control
- Outcome
- All-cause mortality and CV hospitalizations
Methodological detailsrandom effects model, extrapolation to real-world data
- Random effects model
- Extrapolation to real-world data
Pooled result
As reported in the abstract
ATTR-targeted treatment vs ControlRelative risk (95% CI)P value
All-cause mortality; I2 = 35%
0.61(0.52–0.70)
P = 0.13CV hospitalizations; random effects; I2 = 68%
0.69(0.53–0.89)
P = 0.01Further pooled results
All-cause mortality, RCTs only (sensitivity subgroup analysis)
- 28% reduction in all-cause mortality with ATTR-targeted treatment, RCTs only
- RR 0.72, 95% CI: 0.60 to 0.86, I2 = 0%, P = 0.56
- Sensitivity subgroup analysis
NNT to prevent one death (extrapolated to 18238 untreated patients)
- NNT at 2 years
- 10
- NNT at 5 years
- 5
- Extrapolated to epidemiological data on untreated patients
Original publication
Real-World Effectiveness of Targeted Therapies in ATTR Cardiomyopathy: A Meta-Analysis Integrating Population-Based Data. ESC Heart Fail. Published 28 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →